LHLabcorp
Price
+46%1YEnd-of-day closes, not the intraday tick.
Labcorp® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The Company provides insights and accelerates innovations to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. During 2025, the Company’s nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Business segments
Jun 2026 · $3.74BThe company’s own SEC segment disclosure.
- Diagnostics$2.90B78%
- Biopharma Laboratory Services$836.2M22%
Labcorp (LH) reported revenue of $3.81B in Q3 2026 (quarter ended Sep 30, 2026), up 6.9% from the same quarter a year earlier. That came with a gross margin of 29% and net income of $263M (6.9% of revenue). For the full year FY2025, revenue was $14.0B (+7.2% year on year) and net income $877M. Its largest segment in Q2 2026 (quarter ended Jun 30, 2026) was Diagnostics at $2.90B, 78% of the disclosed total, well ahead of Biopharma Laboratory Services at 22%. The next results filing is expected around Feb 16, 2027, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Nov 4, 2026Labcorp to Speak at the UBS Global Healthcare Conference.Regulation FD disclosure · press release
- Oct 28, 2026Nickolo Russo - Investors.Earnings release · press release
- Oct 21, 2026Labcorp Declares Quarterly Dividend.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Diagnostics & Research
The closest names by size in the same industry